The University of Szeged has reinforced its top-rank position in terms of clinical examinations. A Memorandum of Understanding has been signed between the SZTE and the AbbVie Ltd. on the 15th November 2019 to promote the launch of joint clinical projects aiming the establishment of modern therapeutic treatments for patients with oncological, immunological and neurological diseases.
Hundreds of clinical examinations are being conducted at the University of Szeged, as a result which innovative research is carried out at the clinics of Szeged, thus supporting the healing treatment of patients and strengthening the healthcare system of the country. The aim of the Memorandum signed on the 15th November is to promote the pharmaceutical research and development and to assist the recovery.
‘The improvement of Hungarian competitiveness related to clinical examinations is of strategic importance’ Prof. Dr. László Rovó said. The rector of the University of Szeged added that in addition to the promotion of the capacity for research and development of the university, the agreement contributes to an expansion in the number of pharmaceutical examinations. In addition to endorse the launch of new clinical projects, the agreement promotes the establishment of therapeutic treatments for patients with oncological, immunological and neurological diseases.
Dr. Judit Fendler, Chancellor of the University of Szeged highlighted that the aim of the University is to become the educational, research and innovation center of the region and the signing of this agreement greatly contributes to this goal. She added that AbbVie Ltd. is considered as a privileged partner since 30 joint projects has been launched in the last 10 years at the University of Szeged.
Dr. Noémi Balajti, Chief Medical Director of AbbVie Ltd. said that the company is present in 170 countries and around 400 clinical examinations are being conducted in oncology and immunology as well. Joint examinations in dermatology, oncology, hematology and neurology are being carried out together with the University of Szeged. She added that the agreement opens a new chapter for the parties and more clinical examinations can be carried out involving more patients in several therapeutic areas.
‘Important parameters of the ranking of world-class examination sites are the term of contracts and the rapid involvement of patients. This specific framework agreement was made to speed up this process and with its help the administration of examinations to be started will significantly be reduced, therefore patients could receive innovative medication long before their launch in the public market’ Dr. Balázs Bende, head of SZTE Coordinating Office for Clinical Examinations said.
